ACR Appropriateness Criteria® Post-treatment Follow-up Prostate Cancer

J Am Coll Radiol. 2018 May;15(5S):S132-S149. doi: 10.1016/j.jacr.2018.03.019.

Abstract

Diagnosis and management of prostate cancer post treatment is a large and complex problem, and care of these patients requires multidisciplinary involvement of imaging, medical, and surgical specialties. Imaging capabilities for evaluation of men with recurrent prostate cancer are rapidly evolving, particularly with PET and MRI. At the same time, treatment options and capabilities are expanding and improving. These recommendations separate patients into three broad categories: (1) patients status post-radical prostatectomy, (2) clinical concern for residual or recurrent disease after nonsurgical local and pelvic treatments, and (3) metastatic prostate. This article is a review of the current literature regarding imaging in these settings and the resulting recommendations for imaging. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

Keywords: AUC; Appropriate Use Criteria; Appropriateness Criteria; Choline and fluciclovine PET; MRI; Metastatic prostate cancer; Prostate cancer; Recurrent prostate cancer.

Publication types

  • Practice Guideline

MeSH terms

  • Biomarkers, Tumor / blood
  • Contrast Media
  • Evidence-Based Medicine
  • Humans
  • Male
  • Neoplasm Grading
  • Neoplasm Staging
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / diagnostic imaging*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / therapy*
  • Societies, Medical
  • United States

Substances

  • Biomarkers, Tumor
  • Contrast Media
  • Prostate-Specific Antigen